Australia's most trusted
source of pharma news
Posted 16 July 2026 AM
A languishing drug may restart the process for PBS listing with Samsung Bioepis and Organon announcing they have expanded their Development and Commercialisation Agreement to include a fourth biosimilar in Australia.
"We are proud to build on our longstanding partnership with Organon to expand the availability of our biosimilar portfolio for Australian patients," Samsung Bioepis Vice President and Head of Commercial Strategy for International Markets, Jinhan Chung, said. "This expanded agreement reflects Samsung Bioepis' enduring commitment to widening global access to biosimilars."

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.